Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?

[1]  J. Karnon,et al.  Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System , 2018, PharmacoEconomics.

[2]  S. Humphries,et al.  Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. , 2018, Atherosclerosis.

[3]  K. Arnesen,et al.  LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. , 2019, Journal of clinical lipidology.

[4]  M. Banach,et al.  The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland. , 2018, Atherosclerosis.

[5]  Louise B. Russell,et al.  Is Prevention Better Than Cure , 1987 .

[6]  J. Shaw,et al.  Prevalence and treatment of familial hypercholesterolaemia in Australian communities. , 2015, International journal of cardiology.

[7]  G. Watts,et al.  Challenges in the health economics of familial hypercholesterolemia , 2016, Current opinion in lipidology.

[8]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[9]  C. Reid,et al.  Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective , 2018, European journal of preventive cardiology.

[10]  J. Kastelein,et al.  20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. , 2019, The New England journal of medicine.

[11]  Frank M Sanfilippo,et al.  Population Trends of Recurrent Coronary Heart Disease Event Rates Remain High , 2011, Circulation. Cardiovascular quality and outcomes.

[12]  S. Humphries,et al.  Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK , 2017, European heart journal.

[13]  J. Hay,et al.  Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. , 2015, International journal of cardiology.

[14]  Z. Ademi,et al.  A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. , 2013, International journal of cardiology.

[15]  K. Holven,et al.  Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. , 2017, Journal of clinical lipidology.

[16]  C. Cannon,et al.  Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration , 2017, European heart journal.

[17]  Christine Y. Lu,et al.  Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review , 2019, Journal of personalized medicine.

[18]  S. Humphries,et al.  Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register , 2018, Atherosclerosis.

[19]  G. Watts,et al.  Prevalence of Familial Hypercholesterolemia in Adolescents: Potential Value of Universal Screening? , 2016, The Journal of pediatrics.

[20]  G. Watts,et al.  Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. , 2017, Journal of clinical lipidology.

[21]  G. Watts,et al.  Parent–child genetic testing for familial hypercholesterolaemia in an Australian context , 2018, Journal of paediatrics and child health.

[22]  J. Ratcliffe,et al.  Health-related quality of life measured using the EQ-5D–5L: South Australian population norms , 2016, Health and Quality of Life Outcomes.

[23]  T. Vos,et al.  Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study , 2012, BMC Public Health.

[24]  K. Williams,et al.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.

[25]  Philip R. Delio,et al.  Acute and chronic impact of cardiovascular events on health state utilities , 2015, BMC Health Services Research.

[26]  S. Yamashita,et al.  Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. , 2014, International journal of cardiology.

[27]  Z. Ademi,et al.  Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. , 2014, Journal of clinical lipidology.

[28]  E. Smets,et al.  Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence , 2015, Pediatric Drugs.